TGA Internet site archive
The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.
Cost recovery implementation statement 2016-17
V1.0 June 2016
18 July 2016
Appendix 1 - Financial performance by industry sector group
1. Prescription medicines
| Volumes5 | 2014-15 Actual |
2015-16 Forecast |
2016-17 Budget |
2017-18 Estimate |
2018-19 Estimate |
|---|---|---|---|---|---|
| Biological prescription medicines | 461 | 550 | 550 | 550 | 550 |
| Non-biological prescription medicines - higher charge | N/A | 475 | 475 | 475 | 475 |
| Non-biological prescription medicines - lower charge | 4,842 | 5,901 | 5,901 | 5,901 | 5,901 |
| Revenue and expenses | 2014-15 Actual $'m |
2015-16 Forecast $'m |
2016-17 Budget $'m |
2017-18 Estimate $'m |
2018-19 Estimate $'m |
|---|---|---|---|---|---|
| A: Revenue | |||||
| Cost recovery revenue | 65.6 | 68.7 | 70.8 | 72.7 | 75.5 |
| Total A | 65.6 | 68.7 | 70.8 | 72.7 | 75.5 |
| B: Expenses6 | |||||
| Direct | 35.4 | 34.7 | 40.0 | 39.9 | 40.5 |
| Indirect | 22.8 | 22.3 | 25.8 | 25.7 | 26.0 |
| Total B | 58.1 | 57.0 | 65.8 | 65.6 | 66.5 |
| Surplus (deficit) | 7.4 | 11.7 | 5.0 | 7.0 | 9.0 |
2. Over the counter medicines
| Volumes7 | 2014-15 Actual |
2015-16 Forecast |
2016-17 Budget |
2017-18 Estimate |
2018-19 Estimate |
|---|---|---|---|---|---|
| Over the counter medicines | 2,064 | 2,451 | 2,451 | 2,451 | 2,451 |
| Revenue and expenses | 2014-15 Actual $'m |
2015-16 Forecast $'m |
2016-17 Budget $'m |
2017-18 Estimate $'m |
2018-19 Estimate $'m |
|---|---|---|---|---|---|
| A: Revenue | |||||
| Cost recovery revenue | 7.7 | 8.0 | 8.2 | 8.4 | 8.8 |
| Total A | 7.7 | 8.0 | 8.2 | 8.4 | 8.8 |
| B: Expenses8 | |||||
| Direct | 5.1 | 5.0 | 5.7 | 5.7 | 5.8 |
| Indirect | 2.9 | 2.8 | 3.3 | 3.3 | 3.3 |
| Total B | 7.9 | 7.8 | 9.0 | 9.0 | 9.1 |
| Surplus (deficit) | (0.3) | 0.2 | (0.8) | (0.5) | (0.3) |
3. Complementary medicines
| Volumes9 | 2014-15 Actual |
2015-16 Forecast |
2016-17 Budget |
2017-18 Estimate |
2018-19 Estimate |
|---|---|---|---|---|---|
| Registered complementary medicines | 131 | 127 | 127 | 127 | 127 |
| Listed complementary medicines | 8,262 | 9,491 | 9,491 | 9,491 | 9,491 |
| Revenue and expenses | 2014-15 Actual $'m |
2015-16 Forecast $'m |
2016-17 Budget $'m |
2017-18 Estimate $'m |
2018-19 Estimate $'m |
|---|---|---|---|---|---|
| A: Revenue | |||||
| Cost recovery revenue | 11.4 | 12.6 | 13.0 | 13.3 | 13.8 |
| Total A | 11.4 | 12.6 | 13.0 | 13.3 | 13.8 |
| B: Expenses10 | |||||
| Direct | 13.7 | 13.4 | 15.5 | 15.4 | 15.6 |
| Indirect | 9.0 | 8.8 | 10.2 | 10.1 | 10.3 |
| Total B | 22.7 | 22.2 | 25.6 | 25.6 | 25.9 |
| Surplus (deficit) | (11.3) | (9.6) | (12.7) | (12.3) | (12.1) |
4. Medical devices, including in-vitro diagnostic (IVD) devices
| Volumes11 | 2014-15 Actual |
2015-16 Forecast |
2016-17 Budget |
2017-18 Estimate |
2018-19 Estimate |
|---|---|---|---|---|---|
| Included medical devices | 39,124 | 40,480 | 40,480 | 40,480 | 40,480 |
| Other therapeutic goods | 448 | 340 | 340 | 340 | 340 |
| Revenue and expenses | 2014-15 Actual $'m |
2015-16 Forecast $'m |
2016-17 Budget $'m |
2017-18 Estimate $'m |
2018-19 Estimate $'m |
|---|---|---|---|---|---|
| A: Revenue | |||||
| Cost recovery revenue | 32.0 | 31.7 | 32.7 | 33.5 | 34.8 |
| Total A | 32.0 | 31.7 | 32.7 | 33.5 | 34.8 |
| B: Expenses12 | |||||
| Direct | 12.9 | 12.6 | 14.6 | 14.6 | 14.8 |
| Indirect | 11.2 | 11.0 | 12.7 | 12.6 | 12.8 |
| Total B | 24.1 | 23.6 | 27.3 | 27.2 | 27.6 |
| Surplus (deficit) | 7.9 | 8.1 | 5.4 | 6.3 | 7.3 |
5. Good manufacturing practices
| Volumes13 | 2014-15 Actual |
2015-16 Forecast |
2016-17 Budget |
2017-18 Estimate |
2018-19 Estimate |
|---|---|---|---|---|---|
| Low level GMP licence | 116 | 104 | 104 | 104 | 104 |
| High level GMP licence | 162 | 163 | 163 | 163 | 163 |
| Revenue and expenses | 2014-15 Actual $'m |
2015-16 Forecast $'m |
2016-17 Budget $'m |
2017-18 Estimate $'m |
2018-19 Estimate $'m |
|---|---|---|---|---|---|
| A: Revenue | |||||
| Cost recovery revenue | 12.1 | 11.1 | 11.5 | 11.8 | 12.2 |
| Total A | 12.1 | 11.1 | 11.5 | 11.8 | 12.2 |
| B: Expenses14 | |||||
| Direct | 9.3 | 9.1 | 10.5 | 10.5 | 10.7 |
| Indirect | 3.6 | 3.5 | 4.0 | 4.0 | 4.1 |
| Total B | 12.9 | 12.6 | 14.6 | 14.5 | 14.7 |
| Surplus (deficit) | (0.7) | (1.5) | (3.1) | (2.8) | (2.5) |
6. Blood, blood components and biologicals
| Volumes15 | 2014-15 Actual |
2015-16 Forecast |
2016-17 Budget |
2017-18 Estimate |
2018–19 Estimate |
|---|---|---|---|---|---|
| Blood primary site | 5 | 5 | 5 | 5 | 5 |
| Blood secondary site | 79 | 79 | 79 | 79 | 79 |
| Single step manufacturer of human tissue | 10 | 24 | 24 | 24 | 24 |
| Class 2 biological products | 14 | 15 | 15 | 15 | 15 |
| Revenue and expenses | 2014-15 Actual $'m |
2015-16 Forecast $'m |
2016-17 Budget $'m |
2017-18 Estimate $'m |
2018-19 Estimate $'m |
|---|---|---|---|---|---|
| A: Revenue | |||||
| Cost recovery revenue | 2.0 | 2.2 | 2.3 | 2.3 | 2.4 |
| Total A | 2.0 | 2.2 | 2.3 | 2.3 | 2.4 |
| B: Expenses16 | |||||
| Direct | 1.8 | 1.8 | 2.0 | 2.0 | 2.1 |
| Indirect | 1.5 | 1.5 | 1.7 | 1.7 | 1.7 |
| Total B | 3.3 | 3.2 | 3.7 | 3.7 | 3.8 |
| Surplus (deficit) | (1.3) | (1.0) | (1.5) | (1.4) | (1.4) |
7. Other activities
| Revenue and expenses | 2014-15 Actual $'m |
2015-16 Forecast $'m |
2016-17 Budget $'m |
2017-18 Estimate $'m |
2018-19 Estimate $'m |
|---|---|---|---|---|---|
| A: Revenue | |||||
| Revenue | 8.0 | 2.1 | 2.0 | 2.0 | 2.0 |
| Total A | 8.0 | 2.1 | 2.0 | 2.0 | 2.0 |
| B: Expenses | |||||
| Expense | 4.4 | 2.1 | 2.0 | 2.0 | 2.0 |
| Total B | 4.4 | 2.1 | 2.0 | 2.0 | 2.0 |
| Surplus (deficit) | 3.6 | 0.0 | 0.0 | 0.0 | 0.0 |
Footnotes
- Number of entries on the ARTG subject to annual charge.
- Due to restructure in the corporate area, TGA is undertaking a review of its activity based costing model to reflect the new structure. The direct and indirect expenses are derived based on the ratio from the previous model.
- Number of entries on the ARTG subject to annual charge.
- Due to restructure in the corporate area, TGA is undertaking a review of its activity based costing model to reflect the new structure. The direct and indirect expenses are derived based on the ratio from previous model.
- Number of entries on the ARTG subject to annual charge.
- Due to restructure in the corporate area, TGA is undertaking a review of its activity based costing model to reflect the new structure. The direct and indirect expenses are derived based on the ratio from previous model.
- Number of entries on the ARTG subject to annual charge.
- Due to restructure in the corporate area, TGA is undertaking a review of its activity based costing model to reflect the new structure. The direct and indirect expenses are derived based on the ratio from previous model.
- Number of entries on the ARTG subject to annual charge.
- Due to restructure in the corporate area, TGA is undertaking a review of its activity based costing model to reflect the new structure. The direct and indirect expenses are derived based on the ratio from previous model.
- Number of entries on the ARTG subject to annual charge.
- Due to restructure in the corporate area, TGA is undertaking a review of its activity based costing model to reflect the new structure. The direct and indirect expenses are derived based on the ratio from previous model.